Heron Therapeutics (HRTX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$55.5 million.
- Heron Therapeutics' Enterprise Value rose 2172.8% to -$55.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.5 million, marking a year-over-year increase of 2172.8%. This contributed to the annual value of -$59.3 million for FY2024, which is 2627.32% up from last year.
- As of Q3 2025, Heron Therapeutics' Enterprise Value stood at -$55.5 million, which was up 2172.8% from -$40.6 million recorded in Q2 2025.
- Heron Therapeutics' Enterprise Value's 5-year high stood at -$33.2 million during Q2 2023, with a 5-year trough of -$257.7 million in Q2 2021.
- In the last 5 years, Heron Therapeutics' Enterprise Value had a median value of -$77.4 million in 2023 and averaged -$97.6 million.
- Its Enterprise Value has fluctuated over the past 5 years, first soared by 6758.05% in 2022, then plummeted by 10258.39% in 2024.
- Quarter analysis of 5 years shows Heron Therapeutics' Enterprise Value stood at -$157.6 million in 2021, then surged by 46.15% to -$84.9 million in 2022, then increased by 5.24% to -$80.4 million in 2023, then rose by 26.27% to -$59.3 million in 2024, then rose by 6.4% to -$55.5 million in 2025.
- Its Enterprise Value stands at -$55.5 million for Q3 2025, versus -$40.6 million for Q2 2025 and -$50.7 million for Q1 2025.